Form D · Pharmaceuticals
OptiNose, Inc.
Yardley, PA · CIK 0001494650
Offering snapshot reported May 20, 2024 · SEC filing
- Reported sold
- $4.68M Offering amount: $4.68M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 20, 2024 | Initial | $4,680,000 | No comparison | 2 | SEC filing |
| Nov 30, 2021 | Initial | $4,000,000 | No comparison | 2 | SEC filing |
| Aug 19, 2020 | Initial | $250,000 | No comparison | 2 | SEC filing |
| Sep 25, 2019 | Initial | $5,445,599 | No comparison | 2 | SEC filing |
| Apr 7, 2017 | Initial | $35,000,065 | No comparison | 8 | SEC filing |
| Oct 13, 2015 | Amendment | $34,999,943 | $4,999,971vs Aug 4, 2014 | 23 | SEC filing |
| Oct 13, 2015 | Initial | $15,000,000 | No comparison | 21 | SEC filing |
| Aug 4, 2014 | Initial | $29,999,972 | No comparison | 23 | SEC filing |
| Jun 21, 2010 | Initial | $21,055,999 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513751
Source: Form D, filed May 20, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Henrik Bruun Andersen | Executive |
| Eric Bednarski | Director |
| Victor M. Clavelli | Executive |
| Klaas De Boer | Director |
| Kyle Dempsey | Director |
| Per Djupesland | Director |
| Helena Kyttari Djupesland | Executive |
| William F. Doyle | Director |
| R. John Fletcher | Director |
| Tom Gibbs | Executive |
| Keith A. Goldan | Executive |
| Wilhelmus Groenhuysen | Director |
| Sandra L. Helton | Director |
| Tomas J. Heyman | Director |
| Michele Janis | Executive |
| Anthony J. Krick | Executive |
| Ramy A. Mahmoud | Director, Executive |
| Michael F. Marino | Executive |
| Peter K. Miller | Director, Executive |
| Robert P. O'neil | Director |
| Patrick O'neill | Director |
| Catherine E. Owen | Director |
| Jackson Phillips | Director |
| Larry Pickering | Director |
| Joseph C. Scodari | Director |
| Paul Spence | Executive |
| Joshua A. Tamaroff | Director |
| Terrence Terifay | Executive |
| Sriram Venkataraman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1020 Stony Hill Road Suite 300
Yardley, PA, 19067
Yardley, PA, 19067